ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

HIK Hikma Pharmaceuticals Plc

1,918.50
38.00 (2.02%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Hikma Pharmaceuticals Plc LSE:HIK London Ordinary Share GB00B0LCW083 ORD SHS 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  38.00 2.02% 1,918.50 1,925.00 1,927.00 1,937.50 1,887.50 1,903.00 504,022 16:35:27
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 2.88B 190M 0.8594 22.41 4.26B
Hikma Pharmaceuticals Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker HIK. The last closing price for Hikma Pharmaceuticals was 1,880.50p. Over the last year, Hikma Pharmaceuticals shares have traded in a share price range of 1,614.50p to 2,222.00p.

Hikma Pharmaceuticals currently has 221,081,676 shares in issue. The market capitalisation of Hikma Pharmaceuticals is £4.26 billion. Hikma Pharmaceuticals has a price to earnings ratio (PE ratio) of 22.41.

Hikma Pharmaceuticals Share Discussion Threads

Showing 951 to 974 of 1875 messages
Chat Pages: Latest  39  38  37  36  35  34  33  32  31  30  29  28  Older
DateSubjectAuthorDiscuss
14/3/2018
08:37
From memory these have been well over £20 not too long ago - so I guess, market thinks its already in the price.

Anyway,here's a summary.

- Hikma reported an operating loss of $747m in 2017 compared with a operating profit of $302m the previous year as increased competition in its US market weighed on its generics business.

Hikma's generics business reported an operating loss of $1,082m in 2017, largely due to the $1,070m impairment of the West-Ward Columbus business. This came as the firm reduced its expectations for the West-Ward Columbus marketed portfolio and pipeline amid increased pricing pressure.

'The increasingly competitive dynamics of the US market, including intense pricing pressure, had a material impact on our Generics business and, in particular, on West-Ward Columbus, the firm said.

Hikma reported a loss before tax of $738m in 2017, down 451% while core profit before tax was $328m, down 9% compared to 2016.

Operating cash flow rose to $443m in 2017, compared with $293m in 2016.

Group revenue was $1.94bn, down from $1.95bn the previous year.

Global injectables revenue declined by 1% to $776m. In constant currency, global Injectables revenue was in line with 2016.

Generics revenue was $615m in 2017, up from $604m in 2016.

Branded revenue was $536m, down 4% compared with $556m in 2016 as good growth in Egypt, the GCC and Sudan, partially offset by more challenging operating conditions in other markets.

The firm said it expect injectables revenue in 2018 will be in the range of $750m to $800m, while generics revenues will be in the range of $550m to $600 and core generics operating margin in the low single digits.

Said Darwazah, Executive Chairman of Hikma, said: 'We delivered a solid performance in 2017 at a challenging time for our industry, demonstrating the benefit of our diversified business model. Profitability in our Branded business remained stable and our Injectables business was resilient, maintaining strong profitability despite new competitors for our top products and benefiting from our strong market position in the US hospital segment.'

'The increasingly competitive dynamics of the US market, including intense pricing pressure, had a material impact on our Generics business and, in particular, on West-Ward Columbus. This was further impacted by the delay in approval for our generic version of Advair Diskus. As a result of these headwinds, we have had to take an impairment related to the West-Ward Columbus business to reflect our updated view of the fair value of this business.'

broadwood
14/3/2018
08:26
Calling the bottom?
r ball
14/3/2018
08:02
Well I was expecting a huge drop on that impairment charge...but we have been pushed up sharply in the opening auction

Currently uncrossing at 943!!

WTF is going on?

nav_mike
14/3/2018
07:58
FTSE 250-listed Hikma Pharmaceuticals reported revenue of USD1.94 for 2017, down from USD1.95 in 2016, as the drugmaker swung to a reported pretax loss of USD738 million from a profit of USD210 million.The company took a USD920 million charge in the year related to the impairment of West-Ward Columbus' intangible assets. Before exceptional items, profit still fell 9% to USD328 million from USD359 million. Hikma proposed a full-year dividend of 34 cents per share, up from 33 cents the year beforeThe company said it expects Generics revenue to be between USD550 million to USD600 million in 2018, and core operating margin in the low single digits before adjusting for lower depreciation related to the impairment taken in 2017. Generics revenue in 2017 totaled USD615 million, up from USD604 million in 2016.Injectables revenue in 2018 will be in the range of USD750 million to USD800 million, compared to a USD776 million reported for 2017 which was down 1% on 2016, as increased competition in the US is offset by new launches and continued growth in the MENA and Europe."We delivered a solid performance in 2017 at a challenging time for our industry, demonstrating the benefit of our diversified business model," said Hikma Executive Chairman Said Darwazah.
mj19
14/3/2018
07:56
oh dear..bottom line is smashed. Expect sharp drop
sandeep67
14/3/2018
07:41
What will happen today after these results ?
gerrym two
12/3/2018
16:42
Certainly could have been worse today - the drop was no worse than daily noise of the last few weeks.

Hopefully they can come up with a decent set of results, and paint a rosy picture going forward

nav_mike
12/3/2018
09:33
Share price reaction could have been worse.

No point in selling at the bottom, if indeed it should prove so.

broadwood
12/3/2018
08:37
2 year delay
r ball
12/3/2018
08:31
This is old news. Just new detail.

At least now we know where we are with the FDA. New trial will/should produce the expected results. Bit disappointed it's going to take so long though.

As said above, fingers crossed for a decent set of results.

bantam175
12/3/2018
08:07
Oh well at least if the results are half-decent on Wednesday they wont get tarnished by the news we've had today - markets will have digested the implications by then
nav_mike
12/3/2018
08:04
That bid story:

Copycat drug makers on alert as Germany's Stada eyes acquisition spree


"Mr Albrecht was tight-lipped on a UK target but City analysts suggested that beleaguered London-listed firms Vectura and Hikma could fit the bill – two companies developing generic drugs, products with expired patents."

kamitora
12/3/2018
07:52
A bid would suit me.
Suet

suetballs
12/3/2018
07:49
Bad news, heading South I fear.

How much is in the price? It has had a spectacular fall.

broadwood
12/3/2018
07:34
Jeez...perfect timing to nullify the potential bid story in the Telegraph at the weekend

Ho hum

nav_mike
12/3/2018
07:24
For sure that will the share price but I think it will recover quickly
sandeep67
12/3/2018
07:20
Original FDA decision upheld. Hikma to do further work with Advair possibly by early 2019.
sza2002
01/3/2018
19:07
The market ignoring Barclays on HIK - Sweet! - Do these brokers make it up as they go along? (It's a bit like listening to the Horse Racing punters!)

Is there really any credibility in what they have to say? If so, why are there so many varying opinions from different brokers? Would they not all agree on a company's fundamentals and trading position and paint a similar outlook? Been trading over 25 years, I'm still not smart enough to work this one out!! :-/

HIK were tipped several times over Christmas & New Year. Is this a broker looking for discounted prices and wishing to grab a bargain? Then ramp it up from a Sell, to a Hold, to a Buy?.. ...They're all in pole position to do this after all!

nickg100
01/3/2018
16:58
Flippin eck what happened here today?

Went out this morning with price at 825 after the Barclays downgrade, and come back to 871 and blue on the day...

Im sure there were people trading with knowledge of the downgrade yesterday....the BOTs were absolutely relentless all day - or maybe im just too cynical...nah!

nav_mike
01/3/2018
09:13
I bought in here at £20 last year thinking I got a good price ? keep the faith people I'm still hopeful
gozzy90
01/3/2018
08:31
I feel ur pain bro , my avg now about a tenner , ho hum.
death by donut
01/3/2018
08:23
Remind me to thank Barclays after I topped up yesterday - another inspired purchase :)
nav_mike
01/3/2018
08:09
Barclays downgrades to 800p target from 1500.

What they gonna say after results?

bantam175
27/2/2018
17:28
Fingers crossed then; anything along those lines would be welcome.
fhmktg
Chat Pages: Latest  39  38  37  36  35  34  33  32  31  30  29  28  Older

Your Recent History

Delayed Upgrade Clock